The Motley Fool··Motley Fool TranscribingCuris Posts Surprise Profit on Erivedge Sale, Pivots to Lymphoma Pipeline
$CRIS reports $19.4M Q4 earnings from one-time Erivedge sale; refocuses on PCNSL and CLL studies with $20.2M PIPE funding.
CRISearningsclinical trials